These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 30415883)

  • 21. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial.
    Wong CC; Baum J; Silvestro A; Beste MT; Bharani-Dharan B; Xu S; Wang YA; Wang X; Prescott MF; Krajkovich L; Dugan M; Ridker PM; Martin AM; Svensson EC
    Cancer Res; 2020 Dec; 80(24):5597-5605. PubMed ID: 33023946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.
    Libby P
    J Am Coll Cardiol; 2017 Oct; 70(18):2278-2289. PubMed ID: 29073957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
    Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C
    Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation and Atherosclerosis: The End of a Controversy.
    Hansson GK
    Circulation; 2017 Nov; 136(20):1875-1877. PubMed ID: 28916641
    [No Abstract]   [Full Text] [Related]  

  • 29. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From clinical observations to molecular mechanisms and back to patients: the successful circuit of the CANTOS study.
    Lembo G
    Cardiovasc Res; 2018 Jan; 114(1):e3-e5. PubMed ID: 29293914
    [No Abstract]   [Full Text] [Related]  

  • 31. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canakinumab for secondary prevention of atherosclerotic disease.
    Capodanno D; Angiolillo DJ
    Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inflammation and atherosclerosis – last piece of the puzzle has fallen into place].
    Jonasson L; Hansson G
    Lakartidningen; 2017 Oct; 114():. PubMed ID: 29292899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation and CVD in 2017: From clonal haematopoiesis to the CANTOS trial.
    Swirski FK
    Nat Rev Cardiol; 2018 Feb; 15(2):79-80. PubMed ID: 29263444
    [No Abstract]   [Full Text] [Related]  

  • 35. Inflammation and atherosclerosis: fulfilling Koch's postulates.
    Jialal I; Vikram NK
    Ther Adv Cardiovasc Dis; 2018 Jan; 12(1):5-6. PubMed ID: 29187060
    [No Abstract]   [Full Text] [Related]  

  • 36. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
    Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
    Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trial.
    Orkaby AR; Thomson A; MacFadyen J; Besdine R; Forman DE; Travison TG; Ridker PM
    Aging Cell; 2024 Jan; 23(1):e14029. PubMed ID: 37927208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new strategy for the treatment of atherothrombosis - inhibition of inflammation.
    Slíva J; Charalambous C; Bultas J; Karetová D
    Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation in atherosclerotic cardiovascular disease.
    Shah PK; Lecis D
    F1000Res; 2019; 8():. PubMed ID: 31448091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.